Mylan Loses Bid To Dismiss Arthritis Drug Suit
A federal judge on Tuesday refused to dismiss a proposed class action against Mylan Laboratories Inc. that alleges the company's arthritis treatment piroxicam, a generic version of Pfizer Inc.'s Feldene, puts...To view the full article, register now.
Already a subscriber? Click here to view full article